Start-Up Previews (10/20080
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Making Inroads in Predictive Toxicology," features profiles of Cellumen, GliaGen, Horizon Discovery and SimuGen. Plus these Start-Ups Across Health Care: Acacia Pharma, InspireMD, MicroTransponder and Quotient Diagnostics.
You may also be interested in...
InspireMD has come up with a new generation of stents to reduce the risk of embolic showers, injury to the vessel wall, incomplete endothelium healing thrombosis, and other adverse events associated with coronary stenting procedures. The Israeli start-up's MGuard is a line of products consisting of expandable and flexible fishnet-style, micron-level nets that wrap around the stent and block emboli and plaque from detaching from the arterial wall.
Quotient Diagnostics is among the latest group of contenders betting that its diagnostic system can displace existing ones and grow the market for point-of-care diabetes testing. The firm is pinning its hopes not only on a new sort of chemical-binding technology, but more importantly on the incorporation of that science into a diagnostic system that the company claims is simpler, lighter, and smaller than competing point-of-care offerings.
MicroTransponder's MicroStim Pain Management System is a wireless injectable neurostimulator for treating chronic pain. Because it is smaller than implanted spinal cord stimulators, it can be placed outside of the spinal cord nerve and into the peripheral nerves of the arms, legs, and neck. The three components of the system are the Subcutaneous Arrangement of Injectable Neural Transponders unit (an extremely tiny coil injected via a 16-gauge hypodermic needle near the peripheral nerve), an elastic band on the skin containing a larger coil and small battery, and a personal digital assistant or cell phone for the patient to control the stimulation.